Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc.

0.85
EUR
0.00
(0.00%)
-1.04EPS
273.53MMarket Cap
Apr 01Next Earn

Total Valuation

EUR

As of September 30, 2026, Perspective Therapeutics, Inc. carries a market capitalization of 273.53M, placing it among publicly traded companies globally. Its enterprise value stands at 98.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap273.53M
Enterprise Value98.82M

Important Dates

Perspective Therapeutics, Inc.'s next confirmed earnings release is scheduled for April 1, 2027.

Earnings Date4/1/2027

Share Statistics

As of September 30, 2026, Perspective Therapeutics, Inc. has 114.16M shares outstanding.

Shares Outstanding114.16M

Valuation Ratios

These figures are as of September 30, 2026.

PB Ratio1.05
P/TBV Ratio1.22
P/FCF Ratio-2.05
P/OCF Ratio-2.63

Financial Position

As of September 30, 2026, Perspective Therapeutics, Inc. maintains a current ratio of 5.18, meaning it holds 5.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.25, indicating moderate leverage, while an interest coverage ratio of -320.46 demonstrates limited ability to service its debt obligations.

Current Ratio5.18
Quick Ratio5.09
Debt / Equity1.25
Debt / EBITDA-0.03
Interest Coverage-320.46

Financial Efficiency

Over the twelve months ended September 30, 2026, Perspective Therapeutics, Inc. posted a negative return on equity (ROE) of -45.78, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -37.22, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 166.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-45.78
Return on Assets (ROA)-37.22
Employee Count166.00

Stock Price Statistics

EUR

As of the close on November 17, 2026, Perspective Therapeutics, Inc.'s stock has declined approximately 54.73% over the past 52 weeks. The 50-day moving average sits at 1.79, while the 200-day moving average is 2.93.

52-Week Price Change-54.73%
50-Day Moving Average1.79
200-Day Moving Average2.93

Income Statement

EUR

Over the twelve months ended September 30, 2026, Perspective Therapeutics, Inc. generated - - in revenue and converted that into -108.44M in net income, yielding earnings per share of -1.04. EBITDA reached -112.25M, while operating income came in at -116.19M.

Operating Income-116.19M
Pretax Income-109.31M
Net Income-108.44M
EBITDA-112.25M
EBIT-116.19M
Earnings Per Share (EPS)-1.04

Balance Sheet

EUR

As of September 30, 2026, Perspective Therapeutics, Inc. holds 177.96M in cash and equivalents against 3.25M in total debt, resulting in a net debt position of -34.81M. Total book value stands at 260.00M, with working capital of 146.18M providing operational flexibility.

Cash & Cash Equivalents177.96M
Total Debt3.25M
Net Debt-34.81M
Equity (Book Value)260.00M
Book Value Per Share2.28
Working Capital146.18M

Cash Flow

EUR

Perspective Therapeutics, Inc. produced -95.40M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -27.05M in capital expenditures, free cash flow totaled -122.45M - equivalent to -1.17 per share.

Operating Cash Flow-95.40M
Capital Expenditures-27.05M
Free Cash Flow-122.45M
FCF Per Share-1.17

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -48.75: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -53.12, meaning Perspective Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-53.12
FCF Yield-48.75

Stock Splits

Perspective Therapeutics, Inc.'s most recent stock split took place on June 17, 2024 with a 10:1 split ratio.

Last Split Date6/17/2024
Split Ratio10:1

Scores

As of September 30, 2026, Perspective Therapeutics, Inc. has an Altman Z-Score of 0.09, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.09